• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Deroma Leonard James claimed ownership of 187,736 units of Common Stock; $0.0001 par value (SEC Form 3)

    5/1/26 6:31:57 PM ET
    $LABT
    Get the next $LABT alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    DeRoma Leonard James

    (Last)(First)(Middle)
    8031 COOPER CREEK BLVD UNIT 103

    (Street)
    UNIVERSITY PARK FLORIDA 34201

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/17/2026
    3. Issuer Name and Ticker or Trading Symbol
    Lakewood-Amedex Biotherapeutics Inc. [ LABT ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock; $0.0001 par value187,736D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Warrants04/01/201602/29/2028Common Stock40,541$5.92D
    Warrants04/01/201702/29/2028Common Stock13,514$5.92D
    Warrants01/12/201807/11/2028Common Stock33,784$5.92D
    Warrants07/12/202007/11/2030Common Stock8,446$2.37D
    Warrants07/12/202107/11/2031Common Stock8,446$2.78D
    Warrants07/12/202207/11/2032Common Stock8,446$2.13D
    Explanation of Responses:
    /s/ Leonard DeRoma05/01/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $LABT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LABT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LABT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Tucker Joseph Edward

    4 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

    5/6/26 6:20:17 PM ET
    $LABT

    New insider Tucker Joseph Edward claimed no ownership of stock in the company (SEC Form 3)

    3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

    5/6/26 6:19:02 PM ET
    $LABT

    New insider Deroma Leonard James claimed ownership of 187,736 units of Common Stock; $0.0001 par value (SEC Form 3)

    3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Issuer)

    5/1/26 6:31:57 PM ET
    $LABT

    $LABT
    SEC Filings

    View All

    SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.

    424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

    5/26/26 4:06:53 PM ET
    $LABT

    SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.

    424B3 - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

    5/26/26 4:06:16 PM ET
    $LABT

    SEC Form 10-Q filed by Lakewood-Amedex Biotherapeutics Inc.

    10-Q - Lakewood-Amedex Biotherapeutics Inc. (0002079272) (Filer)

    5/22/26 4:55:07 PM ET
    $LABT

    $LABT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lakewood-Amedex Expands Global IP Portfolio for Lead Candidate, Nu-3, Targeting Infected Diabetic Foot Ulcers

    Patent portfolio now includes 71 granted patents and 28 pending patent applications, covering composition of matter, formulation, and use patentsSARASOTA, Fla., May 27, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced an expansion of its global intellectual property portfolio with the issuance of two patents, one each in Australia and New Zealand respectively.

    5/27/26 8:02:00 AM ET
    $LABT

    Lakewood-Amedex Biotherapeutics Announces Positive Data for the Advancement of Lead Candidate, Nu-3, in Infected Diabetic Foot Ulcers

    Key formulation, delivery and manufacturing steps completed in preparation for planned Phase 2 clinical trial SARASOTA, Fla., May 18, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT, the ", Company", )), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive data for its lead compound, Nu-3, as it advances towards a Phase 2 trial. Nu-3 is being developed as a topically delivered treatment for mildly infected diabetic foot ulcers (iDFU) designed to reduce the risk of antimicrobial resistance (AMR).

    5/18/26 8:02:00 AM ET
    $LABT

    Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3

    Specialized CRO partnership supports Phase 2 program to advance Nu-3 toward potential registration pathway in large, underserved iDFU marketSARASOTA, Fla., May 12, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for locally treatable infectious diseases called the Bisphosphocin® class, today announced that it has entered into an agreement with Professional Education and Research Institute LLC (PERI) to serve as the contract research organization (CRO) for its upcoming Phase 2 clinical program of Nu-3, the Company's lead Bisphosphocin® product for the

    5/12/26 8:02:00 AM ET
    $LABT

    $LABT
    Leadership Updates

    Live Leadership Updates

    View All

    Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors

    Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listingSARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ:LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced the appointment of Joseph Tucker, Ph.D., Chief Executive Officer of Enveric Biosciences (NASDAQ:ENVB), to its Board of Directors. Dr. Tucker's appointment follows Lakewood-Amedex Biotherapeutics' recent direct listing on Nasdaq and represents a key step in strengthening the Company's governance

    4/28/26 7:33:00 AM ET
    $ENVB
    $LABT
    Biotechnology: Pharmaceutical Preparations
    Health Care